Vaxart, Inc. VXRT
We take great care to ensure that the data presented and summarized in this overview for Vaxart, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VXRT
View all-
Vanguard Group Inc Valley Forge, PA8.45MShares$7.35 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.19MShares$1.91 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.89MShares$1.64 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$1.54 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.5MShares$1.3 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny924KShares$804,1410.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il769KShares$669,4360.0% of portfolio
-
Qube Research & Technologies LTD London, X0697KShares$606,6920.0% of portfolio
-
State Street Corp Boston, MA584KShares$507,8580.0% of portfolio
-
Marshall Wace, LLP London, X0533KShares$463,7780.0% of portfolio
Latest Institutional Activity in VXRT
Top Purchases
Top Sells
About VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Insider Transactions at VXRT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,902
-1.09%
|
$3,902
$1.3 P/Share
|
|
Mar 28
2024
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,292
-1.0%
|
$3,292
$1.3 P/Share
|
|
Mar 18
2024
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+27.12%
|
-
|
|
Mar 18
2024
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+17.64%
|
-
|
|
Mar 18
2024
|
Edward B Berg SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+24.95%
|
-
|
|
Mar 18
2024
|
James F. Cummings Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+21.42%
|
-
|
|
Mar 18
2024
|
Steven Lo President, Chief Exec Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Feb 02
2024
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,220
-2.72%
|
$9,220
$1.2 P/Share
|
|
Feb 02
2024
|
Edward B Berg SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,220
-4.85%
|
$9,220
$1.2 P/Share
|
|
Feb 02
2024
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,965
-3.21%
|
$7,965
$1.2 P/Share
|
|
Dec 15
2023
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,943
-3.77%
|
$0
$0.63 P/Share
|
|
Dec 08
2023
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,151
-18.22%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,288
-9.18%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
Edward B Berg SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
33,752
-15.09%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,409
-11.24%
|
$0
$0.71 P/Share
|
|
Jun 26
2023
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,922
+21.98%
|
-
|
|
Jun 26
2023
|
W. Mark Watson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+14.9%
|
-
|
|
Jun 26
2023
|
David E. Wheadon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+33.33%
|
-
|
|
Jun 26
2023
|
Robert A. Yedid Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+28.51%
|
-
|
|
Jun 26
2023
|
Michael J. Finney Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+1.09%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 669K shares |
|---|
| Payment of exercise price or tax liability | 174K shares |
|---|